Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
about
Anti-α4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infectionNMR structure of integrin α4 cytosolic tail and its interactions with paxillinTherapeutic decisions in multiple sclerosis: moving beyond efficacyHepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Natalizumab in the treatment of multiple sclerosisAnti-inflammatory Effects of Flavonoids on TNBS-induced Colitis of RatsVascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse.Protection from experimental colitis by theaflavin-3,3'-digallate correlates with inhibition of IKK and NF-kappaB activation.Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumabIntegrin antagonists are effective and safe for Crohn's disease: a meta-analysisα4-Integrin Antibody Treatment Blocks Monocyte/Macrophage Traffic to, Vascular Cell Adhesion Molecule-1 Expression in, and Pathology of the Dorsal Root Ganglia in an SIV Macaque Model of HIV-Peripheral Neuropathy.Treatment of inflammatory bowel disease: a review of medical therapy.An integrin-alpha4-14-3-3zeta-paxillin ternary complex mediates localised Cdc42 activity and accelerates cell migrationResveratrol Pretreatment Ameliorates TNBS Colitis in Rats.Biologic targeting in the treatment of inflammatory bowel diseases.Anti-adhesion molecule therapy for inflammatory bowel diseaseCombination Therapy of PEG-HM-3 and Methotrexate Retards Adjuvant-Induced Arthritis.Macrophage Polarization in AIDS: Dynamic Interface between Anti-Viral and Anti-Inflammatory Macrophages during Acute and Chronic Infection.Current directions of biologic therapies in inflammatory bowel disease.The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis modelClinical experience of natalizumab in Crohn's disease patients in a restricted distribution program.Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis.
P2860
Q27322602-0457CBF2-1BB6-4066-99B9-7678399415CCQ28485876-D21A5380-587F-4604-A8AD-D49BB656DB22Q28541039-7970420F-C49B-4569-ABA8-A98CE5F354C1Q33654733-24A972DC-D773-4374-A822-3C2753DCA146Q34409340-0B07A540-AEA3-488E-A2C3-D5C617C7C11EQ34980451-F1E66306-B5E6-4B0A-8635-BF06E2C7B247Q35083689-52C4830E-42E5-4A0C-971A-169C993C649EQ35119930-7F751F53-DC0B-41E9-ADE3-721C3157D0A6Q35205472-DEFACB0C-B68D-48D8-9EE9-C82304D258A6Q35473311-53D683B1-8D89-4DDE-BE90-47B5E5351539Q37057132-DF29DC90-40EA-4514-A676-C3C0F54A193AQ37058862-CF38E6D0-C280-418B-9893-16E5EDFC8E43Q37186864-105C37A2-A66D-4E28-9214-6018F88061DCQ37204037-6AFCAAE0-90BC-4CDF-AAE5-3668DC9A1B32Q37303206-D61EDF7C-FB94-4F2B-88DE-65A9A4B5AFEEQ37823325-71A284BF-32BD-4BCD-A60E-73365EDF3147Q38650245-B746ACF1-CB74-49DF-A337-B164B225F390Q40937611-C57614A0-D289-4DAE-8F66-68349DE2E237Q41174352-44A1778F-D44F-446C-B02E-9709F332D470Q42490778-A566A32B-BBE9-4063-AA1C-B42B499BD7E2Q46118227-F8CD79FF-890E-4C32-B475-4A3C7D59621BQ52720739-EFC8D7A4-F707-4FC0-A328-1242B9858C3B
P2860
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@ast
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@en
type
label
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@ast
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@en
prefLabel
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@ast
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@en
P1476
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin.
@en
P2093
Ted A Yednock
William J Sandborn
P304
P356
10.1016/J.AMJGASTROENTEROL.2003.08.009
P407
P577
2003-11-01T00:00:00Z